In-hospital and long-term mortality for acute heart failure: analysis at the time of admission to the emergency department.


Journal

ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191

Informations de publication

Date de publication:
10 2020
Historique:
received: 03 11 2019
revised: 28 05 2020
accepted: 02 06 2020
pubmed: 27 6 2020
medline: 22 6 2021
entrez: 27 6 2020
Statut: ppublish

Résumé

Acute heart failure (AHF) leads to a drastic increase in mortality and rehospitalization. The aim of the study was to identify prognostic variables in a real-life population of AHF patients admitted to the emergency department with acute shortness of breath. We evaluated potential predictors of mortality in 728 consecutive patients admitted to the emergency department with AHF. Possible predictors of all-cause and cardiovascular (CV) mortality were investigated by Cox and Fine and Gray models at multivariable analysis. Among the 728 patients, 256 died during the entire follow-up, 142 of these due to CV cause. The 1 year mortality rate was 20%, with the highest risk of death during the index hospitalization (with 8% estimate in-hospital mortality at 30 days). A higher risk of events during the index hospitalization was more evident for the CV deaths, for which we found a cumulative 1 year incidence of 12% with a cumulative incidence in the first 30 days of hospitalization of about 5%. At multivariable analysis, age (P < 0.001), New York Heart Association (NYHA) class IV vs. I-II-III (P = 0.001), systolic blood pressure (P < 0.001), non-cardiac co-morbidities (≥3 vs. 0, P = 0.05), oxygen saturation (P = 0.03), serum creatinine (P < 0.001), and left ventricular ejection fraction (LVEF) (40-49% vs. <40%, P = 0.004; ≥50% vs. <40%, P = 0.003) were independent predictors of all-cause mortality during the entire follow-up. Age (P = 0.03), systolic blood pressure (P = 0.01), oxygen saturation (P = 0.03), serum creatinine (P = 0.02), and LVEF (40-49% vs. <40%, P = 0.03; ≥50% vs. <40%, P = 0.004) were independent predictors of CV mortality during the entire follow-up. NYHA class IV vs. I-II-III (P < 0.001), serum creatinine (P = 0.01), and LVEF (40-49% vs. <40%, P = 0.02; ≥50% vs. <40%, P < 0.001) remained independent predictors for in-hospital death, while only serum creatinine (P = 0.04), LVEF (40-49% vs. <40%: 0.32, P = 0.04; ≥50% vs. <40%, P < 0.001), and NYHA class vs. I-II-III (P = 0.02) remained predictors for in-hospital CV mortality. In this real-life cohort of patients with AHF, the results showed a similar mortality rate comparing with other analysis and with the most important registries. Age, NYHA class IV, systolic blood pressure, creatinine levels, sodium levels, and ejection fraction were independent predictors of 1 year mortality, while LVEF <40% was the only predictor of both all-cause mortality and CV mortality.

Identifiants

pubmed: 32588981
doi: 10.1002/ehf2.12847
pmc: PMC7524058
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2650-2661

Informations de copyright

© 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

Références

Clin Res Cardiol. 2012 Aug;101(8):663-72
pubmed: 22407461
Int J Cardiol. 2017 Mar 1;230:585-591
pubmed: 28057363
Clin Res Cardiol. 2010 Feb;99(2):107-13
pubmed: 19921298
Int J Cardiol. 2019 Dec 1;296:103-108
pubmed: 31324396
Medicine (Baltimore). 2017 Jul;96(27):e7401
pubmed: 28682895
Lancet. 2017 Oct 28;390(10106):1981-1995
pubmed: 28460827
Am J Cardiol. 2003 Sep 1;92(5):625-8
pubmed: 12943893
Eur J Heart Fail. 2012 Nov;14(11):1257-64
pubmed: 22764184
J Am Heart Assoc. 2013 May 15;2(3):e000053
pubmed: 23676294
Int J Cardiol. 2016 Nov 1;222:531-537
pubmed: 27509222
Circ Heart Fail. 2011 Nov;4(6):724-32
pubmed: 21900185
Eur J Heart Fail. 2019 Nov;21(11):1338-1352
pubmed: 31127678
Circulation. 1996 Dec 1;94(11):2807-16
pubmed: 8941106
Heart Vessels. 2017 Dec;32(12):1498-1505
pubmed: 28698994
Int J Cardiol. 2010 Feb 4;138(3):281-9
pubmed: 18817994
J Am Coll Cardiol. 2006 Jan 3;47(1):76-84
pubmed: 16386668
ESC Heart Fail. 2020 Oct;7(5):2650-2661
pubmed: 32588981
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
Am J Cardiol. 2018 Apr 15;121(8):969-974
pubmed: 29477488
PLoS One. 2017 Dec 19;12(12):e0188938
pubmed: 29261675
J Am Coll Cardiol. 2008 Jul 29;52(5):347-56
pubmed: 18652942
J Cardiovasc Med (Hagerstown). 2018 Dec;19(12):706-716
pubmed: 30222663
Am Heart J. 2007 Jun;153(6):1021-8
pubmed: 17540205
Eur J Heart Fail. 2017 Oct;19(10):1242-1254
pubmed: 28463462
Eur J Heart Fail. 2010 Feb;12(2):122-8
pubmed: 20083622
Int J Cardiol. 2014 Feb 15;171(3):368-76
pubmed: 24398230
Eur J Heart Fail. 2018 Dec;20(12):1664-1672
pubmed: 30311713
Eur J Heart Fail. 2019 Jul;21(7):921-929
pubmed: 30933403
Circ J. 2016 Nov 25;80(12):2473-2481
pubmed: 27795486
Eur J Heart Fail. 2014 Apr;16(4):461-9
pubmed: 24515441
Eur J Heart Fail. 2015 Apr;17(4):374-84
pubmed: 25739882
JAMA. 2006 Nov 8;296(18):2217-26
pubmed: 17090768
JAMA. 2005 Feb 2;293(5):572-80
pubmed: 15687312
Eur J Intern Med. 2017 Jan;37:56-63
pubmed: 27692931
Circulation. 2005 May 17;111(19):2454-60
pubmed: 15867182
JACC Heart Fail. 2013 Dec;1(6):488-96
pubmed: 24622000
Eur J Heart Fail. 2016 Jun;18(6):613-25
pubmed: 27324686
Eur J Heart Fail. 2017 Nov;19(11):1414-1423
pubmed: 28463464
Int J Cardiol. 2018 Feb 15;253:97-104
pubmed: 29249470
Int Heart J. 2018 Sep 26;59(5):1052-1058
pubmed: 30101847
Eur J Heart Fail. 2014 Mar;16(3):309-16
pubmed: 24464774
Am Heart J. 1999 Jul;138(1 Pt 1):78-86
pubmed: 10385768
Eur J Heart Fail. 2008 Feb;10(2):188-95
pubmed: 18279773
Am Heart J. 2010 Jun;159(6):949-955.e1
pubmed: 20569705
Eur Heart J. 2017 Jun 21;38(24):1883-1890
pubmed: 28329163
JAMA. 2007 May 2;297(17):1883-91
pubmed: 17473298
Am Heart J. 2013 Feb;165(2):216-25
pubmed: 23351825
Eur Heart J. 2006 Dec;27(24):3011-7
pubmed: 17127708
ESC Heart Fail. 2018 Dec;5(6):1008-1016
pubmed: 30211480
Clin Res Cardiol. 2017 May;106(5):359-368
pubmed: 27999929

Auteurs

Carlo Lombardi (C)

Department of Medical and Surgical Specialties, Radiological Sciences and Public Health University, University of Brescia Spedali Civili of Brescia, Brescia, Italy.

Giulia Peveri (G)

Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.

Dario Cani (D)

Department of Medical and Surgical Specialties, Radiological Sciences and Public Health University, University of Brescia Spedali Civili of Brescia, Brescia, Italy.

Federica Latta (F)

Department of Medical and Surgical Specialties, Radiological Sciences and Public Health University, University of Brescia Spedali Civili of Brescia, Brescia, Italy.

Andrea Bonelli (A)

Department of Medical and Surgical Specialties, Radiological Sciences and Public Health University, University of Brescia Spedali Civili of Brescia, Brescia, Italy.

Daniela Tomasoni (D)

Department of Medical and Surgical Specialties, Radiological Sciences and Public Health University, University of Brescia Spedali Civili of Brescia, Brescia, Italy.

Marco Sbolli (M)

Department of Medical and Surgical Specialties, Radiological Sciences and Public Health University, University of Brescia Spedali Civili of Brescia, Brescia, Italy.

Alice Ravera (A)

Department of Medical and Surgical Specialties, Radiological Sciences and Public Health University, University of Brescia Spedali Civili of Brescia, Brescia, Italy.

Valentina Carubelli (V)

Department of Medical and Surgical Specialties, Radiological Sciences and Public Health University, University of Brescia Spedali Civili of Brescia, Brescia, Italy.

Nicola Saccani (N)

Department of Medical and Surgical Specialties, Radiological Sciences and Public Health University, University of Brescia Spedali Civili of Brescia, Brescia, Italy.

Claudia Specchia (C)

Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.

Marco Metra (M)

Department of Medical and Surgical Specialties, Radiological Sciences and Public Health University, University of Brescia Spedali Civili of Brescia, Brescia, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH